BACKGROUND: Direct-acting antivirals (DAAs) have greatly improved the treatment of HCV infection. To improve response and prevent resistance, combination regimens have been the focus of clinical development. Regimens are often first assessed in vitro, with most combination studies to date using subgenomic replicon systems, which do not replicate the complete HCV life cycle and preclude study of entry and assembly inhibitors. Infectious full-length HCV systems have been developed and are being used to test drug efficacy. METHODS: Using cell-based HCV Con1b replicon and an infectious full-length HCV (HCVcc-Luc) infection system, we systematically tested the synergy, additivity or antagonism of combinations of protease, NS5A and nucleotide NS5B inhibitor classes as well as the combination of these DAAs with host-targeting agent cyclosporin A or non-antibody entry inhibitor (S)-chlorcyclizine. Two computational software packages, MacSynergyII and CalcuSyn, were used for data analysis. RESULTS: Combinations between different classes showed good consistency across the two viral assay systems and two software platforms. Combinations between NS5A and nucleotide NS5B inhibitors were synergistic, while combinations of protease inhibitors with the other two classes were additive to slightly antagonistic. As expected, combinations of antivirals of the same class were additive. Combination studies between these DAA classes and cyclosporin A or (S)-chlorcyclizine demonstrated additive to synergistic effects and highly synergistic effects, respectively. Combinations of these drugs did not show any added or unexpected cytotoxicity. CONCLUSIONS: Our results show that in vitro combination studies of anti-HCV DAAs in the HCVcc system may provide useful guidance for drug combination designs in clinical studies. We also demonstrate that these DAAs in combination with host-targeting agents or entry inhibitors may improve HCV treatment response.
BACKGROUND: Direct-acting antivirals (DAAs) have greatly improved the treatment of HCV infection. To improve response and prevent resistance, combination regimens have been the focus of clinical development. Regimens are often first assessed in vitro, with most combination studies to date using subgenomic replicon systems, which do not replicate the complete HCV life cycle and preclude study of entry and assembly inhibitors. Infectious full-length HCV systems have been developed and are being used to test drug efficacy. METHODS: Using cell-based HCV Con1b replicon and an infectious full-length HCV (HCVcc-Luc) infection system, we systematically tested the synergy, additivity or antagonism of combinations of protease, NS5A and nucleotide NS5B inhibitor classes as well as the combination of these DAAs with host-targeting agent cyclosporin A or non-antibody entry inhibitor (S)-chlorcyclizine. Two computational software packages, MacSynergyII and CalcuSyn, were used for data analysis. RESULTS: Combinations between different classes showed good consistency across the two viral assay systems and two software platforms. Combinations between NS5A and nucleotide NS5B inhibitors were synergistic, while combinations of protease inhibitors with the other two classes were additive to slightly antagonistic. As expected, combinations of antivirals of the same class were additive. Combination studies between these DAA classes and cyclosporin A or (S)-chlorcyclizine demonstrated additive to synergistic effects and highly synergistic effects, respectively. Combinations of these drugs did not show any added or unexpected cytotoxicity. CONCLUSIONS: Our results show that in vitro combination studies of anti-HCV DAAs in the HCVcc system may provide useful guidance for drug combination designs in clinical studies. We also demonstrate that these DAAs in combination with host-targeting agents or entry inhibitors may improve HCV treatment response.
Authors: Peter Ferenci; David Bernstein; Jacob Lalezari; Daniel Cohen; Yan Luo; Curtis Cooper; Edward Tam; Rui T Marinho; Naoky Tsai; Anders Nyberg; Terry D Box; Ziad Younes; Pedram Enayati; Sinikka Green; Yaacov Baruch; Bal Raj Bhandari; Florin Alexandru Caruntu; Thomas Sepe; Vladimir Chulanov; Ewa Janczewska; Giuliano Rizzardini; Judit Gervain; Ramon Planas; Christophe Moreno; Tarek Hassanein; Wangang Xie; Martin King; Thomas Podsadecki; K Rajender Reddy Journal: N Engl J Med Date: 2014-05-04 Impact factor: 91.245
Authors: Muhammad N Zahid; Marine Turek; Fei Xiao; Viet Loan Dao Thi; Maryse Guérin; Isabel Fofana; Philippe Bachellier; John Thompson; Leen Delang; Johan Neyts; Dorothea Bankwitz; Thomas Pietschmann; Marlène Dreux; François-Loïc Cosset; Fritz Grunert; Thomas F Baumert; Mirjam B Zeisel Journal: Hepatology Date: 2012-12-28 Impact factor: 17.425
Authors: Donna M Tscherne; Christopher T Jones; Matthew J Evans; Brett D Lindenbach; Jane A McKeating; Charles M Rice Journal: J Virol Date: 2006-02 Impact factor: 5.103
Authors: Muhammad Tahir Ul Qamar; Arooma Maryam; Iqra Muneer; Feng Xing; Usman Ali Ashfaq; Faheem Ahmed Khan; Farooq Anwar; Mohammed H Geesi; Rana Rehan Khalid; Sadaf Abdul Rauf; Abdul Rauf Siddiqi Journal: Sci Rep Date: 2019-02-05 Impact factor: 4.379
Authors: Israr Fatima; Sajjad Ahmad; Mubarak A Alamri; Muhammad Usman Mirza; Muhammad Tahir Ul Qamar; Abdur Rehman; Farah Shahid; Eid A Alatawi; Faris F Aba Alkhayl; Wafa Abdullah Al-Megrin; Ahmad Almatroudi Journal: Sci Rep Date: 2022-06-03 Impact factor: 4.996
Authors: Tesia Bobrowski; Lu Chen; Richard T Eastman; Zina Itkin; Paul Shinn; Catherine Chen; Hui Guo; Wei Zheng; Sam Michael; Anton Simeonov; Matthew D Hall; Alexey V Zakharov; Eugene N Muratov Journal: bioRxiv Date: 2020-06-30
Authors: Adam Rolt; Daniel C Talley; Seung Bum Park; Zongyi Hu; Andrés Dulcey; Christopher Ma; Parker Irvin; Madeleine Leek; Amy Q Wang; Andrew V Stachulski; Xin Xu; Noel Southall; Marc Ferrer; T Jake Liang; Juan J Marugan Journal: J Med Chem Date: 2021-06-29 Impact factor: 7.446
Authors: Mubarak A Alamri; Muhammad Tahir Ul Qamar; Muhammad Usman Mirza; Safar M Alqahtani; Matheus Froeyen; Ling-Ling Chen Journal: J Pharm Anal Date: 2020-08-28